ReviewHistology and histopathology2026
Muscle atrophy following anterior cruciate ligament reconstruction: A narrative review.
Review in Histology and histopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Muscle weakness is a common issue following anterior cruciate ligament (ACL) reconstruction and is closely linked to muscle atrophy. Preventing or reducing this atrophy is a key goal of rehabilitation. This review summarizes current knowledge on muscle atrophy after ACL reconstruction, including its spatial distribution, time course, underlying mechanisms, and potential interventions. Atrophy affects multiple lower limb muscles and may be influenced by the type of graft used. Tendon harvesting appears to negatively impact the muscle belly of the donor muscle, while atrophy may also occur in the contralateral limb independently of graft harvesting. Muscle atrophy is often already present before surgery and tends to worsen postoperatively. Although partial recovery may occur, long-term deficits are frequently observed. At the muscle fiber level, evidence is inconsistent regarding which fiber types are more vulnerable to atrophy. A transient shift toward faster fiber types has been reported after surgery. On the cellular and molecular level, satellite cell depletion via apoptosis may hinder muscle regrowth and thereby contribute to persistent muscle atrophy. Concurrently, increased expression of myostatin, atrogin-1, and muscle RING-finger-1, along with postoperative inflammation, may promote protein degradation, further exacerbating muscle atrophy. Rehabilitation strategies that involve early immobilization or non-weight bearing may exacerbate atrophy. Interventions such as eccentric training, neuromuscular electrical stimulation, blood flow restriction training, pharmacological agents, and nutritional support demonstrate potential, but no definitive treatment has been established. Future studies using appropriate animal models to clarify the molecular mechanisms of muscle atrophy will be crucial for developing effective therapies.
Indexed as
Identifiers
40685995What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.